Trishula Therapeutics Initiates Phase 2 Study of TTX-030, an Anti-CD39 Antibody, for First-Line Metastatic Pancreatic Cancer Patients
Friday, November 10, 2023
Trishula Therapeutics, Inc., a privately held biotechnology company in the clinical stage, has announced the commencement of a Phase 2 trial to assess the safety and effectiveness of TTX-030, an innovative anti-CD39 antibody. This trial will investigate the potential of TTX-030 in combination with chemotherapy, with or without budigalimab (an experimental anti-PD-1 antibody), as compared to chemotherapy alone. The goal is to establish TTX-030 as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma.
Trishula Therapeutics, emphasized the urgent need for better treatment options for pancreatic cancer. Singhal expressed optimism about advancing the treatment landscape with TTX-030, potentially offering benefits to individuals with advanced pancreatic cancer.
The study aims to enroll around 180 patients on a global scale. Participants will be randomly assigned to one of three study groups: TTX-030 with chemotherapy (gemcitabine and nab-paclitaxel), TTX-030 with chemotherapy plus budigalimab, or chemotherapy alone. The primary focus of the trial is to evaluate progression-free survival (PFS) in a population enriched with specific biomarkers. Secondary endpoints include PFS in the overall patient population, safety, objective response rate, duration of response, and overall survival. Additional details about the study can be found at the following link: [Insert clinicaltrials.gov link].
Trishula will continue its development of TTX-030 in collaboration with AbbVie Inc. According to their collaboration agreement, AbbVie will have an exclusive option to license TTX-030 for further development upon the conclusion of this Phase 2 study.
TTX-030 is an innovative anti-CD39 antibody that has the potential to be a pioneer in its class. It is designed to inhibit the activity of CD39, an enzyme responsible for converting adenosine triphosphate (ATP) into adenosine monophosphate (AMP), which is the initial step in generating adenosine within the tumor microenvironment. TTX-030's role is to prevent the creation of immune-suppressive extracellular adenosine and maintain high levels of immune-activating extracellular ATP. This action stimulates dendritic and myeloid-derived cells, promoting both innate and adaptive anti-tumor immunity.
Source: prnewswire.com
